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Cholera toxin (CT) moves from the plasma membrane to the endoplasmic reticulum (ER) by retrograde
vesicular traffic. In the ER, the catalytic CTA1 polypeptide dissociates from the rest of the toxin and enters
the cytosol by a process that involves the quality control mechanism of ER-associated degradation (ERAD).
The cytosolic CTA1 then ADP ribosylates Gs, resulting in adenylate cyclase activation and intoxication of the
target cell. It is hypothesized that the C-terminal A13 subdomain of CTA1 plays two crucial roles in the
intoxication process: (i) it contains a hydrophobic domain that triggers the ERAD mechanism and (ii) it
facilitates interaction with the cytosolic ADP-ribosylation factors (ARFs) that serve as allosteric activators of
CTA1. In this study, we examined the role(s) of the CTA13 subdomain in CT intoxication. Full-length CTA1
constructs and truncated CTA1 constructs lacking the A13 subdomain were generated and used to conduct
two-hybrid studies of interactions with ARF6, in vitro enzyme assays, in vivo toxicity assays, and in vivo
processing/degradation assays. Direct, plasmid-mediated expression of CTA1 constructs in the ER or cytosol
of transfected CHO cells was used to perform the in vivo assays. With these methods, we found that the A13
subdomain of CTA1 is important both for interaction with ARF6 and for full expression of enzyme activity in
vivo. Surprisingly, however, the A13 subdomain was not required for ERAD-mediated passage of CTA1 from
the ER to the cytosol. A possible alternative trigger for CTA1 to activate the ERAD mechanism is discussed.
Cholera toxin (CT), produced by Vibrio cholerae, is an AB5-
type protein toxin that consists of an A moiety with latent
enzymatic activity and a cell-binding B moiety (reviewed in
references 2 and 35). The A moiety is initially synthesized as a
single CTA polypeptide that undergoes proteolytic processing
to yield a disulfide-linked A1/A2 heterodimer. CTA1 is a 22-
kDa ADP ribosyltransferase with three distinct subdomains:
CTA11 (residues 1 to 132) comprises the catalytic core of the
toxin; CTA12 (residues 133 to 161) is a short, flexible subdo-
main; and CTA13 (residues 162 to 192) is a globular region
that interfaces with CTA11 and has many hydrophobic residues
and a single cysteine residue that provides the disulfide linkage
to CTA2 (52). The 5.5-kDa CTA2 polypeptide maintains nu-
merous noncovalent interactions with the B moiety and
thereby acts as a linker between the catalytic and cell-binding
components of CT. The homopentameric B moiety of CT is
assembled from 11.6-kDa monomers, binds to GM1 ganglio-
sides on the eukaryotic plasma membrane, and serves as a
vehicle for CTA1 delivery to the endoplasmic reticulum (ER)
(3, 15, 33).
CT is internalized from the eukaryotic plasma membrane by
an endocytic mechanism that utilizes lipid rafts (27, 51). The
active pool of internalized toxin subsequently moves to the
endoplasmic reticulum by retrograde vesicular transport (13,
14, 19, 23, 26, 29). In the ER, the disulfide bond linking CTA1
to CTA2/CTB5 is reduced (18, 25, 45). Protein disulfide
isomerase mediates the dissociation of CTA1 from CTA2/
CTB5, and CTA1 is then translocated to the cytosol in a pro-
cess involving the quality control system of ER-associated deg-
radation (ERAD) (30, 39–41, 44–46, 50). The cytosolic pool of
CTA1 ADP ribosylates and irreversibly activates Gs. Acti-
vated Gs stimulates the action of adenylate cyclase, which in
turn leads to elevated levels of intracellular cyclic AMP
(cAMP). Chloride efflux into the intestinal lumen is triggered
by cAMP-dependent signaling events, and the resulting os-
motic movement of water into the gut generates the massive
watery diarrhea characteristic of cholera (reviewed in refer-
ences 9 and 35).
The CTA13 subdomain is thought to be involved with two
important events in the process of cholera intoxication: (i) it
may act as a trigger for ERAD-mediated export to the cytosol,
and (ii) it may promote an interaction with the cytosolic ADP-
ribosylation factors (ARFs) that serve as allosteric activators of
CTA1. Both of these events are discussed in more detail below.
ERAD recognizes misfolded or misassembled proteins in
the ER and exports them to the cytosol for ubiquitination and
proteasomal degradation (11, 20, 46). A hydrophobic region in
the CTA13 subdomain, exposed when CTA1 dissociates from
holotoxin, was postulated to act as a signal for protein misfold-
ing and would therefore trigger the ERAD-mediated export of
CTA1 into the cytosol (4). CTA1 is believed to avoid ubiquitin-
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dependent proteasomal degradation in the cytosol, because it
has only two lysine residues to serve as potential sites for
ubiquitination (4, 28). Other plant and bacterial toxins are also
thought to masquerade as misfolded proteins in order to ex-
ploit ERAD for entry into the cytosol (4, 17). Hydrophobic
regions in the A moieties of two of these toxins, ricin and Shiga
toxin, have been implicated in toxin transfer from the ER to
the cytosol (32, 36). However, no studies have yet directly
addressed the role of the hydrophobic CTA13 subdomain in
CTA1 passage from the ER to the cytosol.
ARFs are low-molecular-weight GTPases involved with
membrane trafficking in the biosynthetic and endocytic trans-
port pathways (48). In vitro, ARFs also act as allosteric acti-
vators of the catalytic activity of CTA1 (48). Several residues in
the CTA13 subdomain are important for ARF interaction with
CTA1 in a bacterial two-hybrid system, and holotoxins con-
taining mutations in these residues exhibit little toxicity (7).
Although the reduced toxicity of these CT mutants could have
resulted from the loss of in vivo ARF interaction, mutations in
the A13 subdomain could also inhibit toxicity through alter-
ations to the enzymatic activity of CT, the trafficking of CT to
the ER, CTA1 entry into the cytosol, or the in vivo stability of
either the CT holotoxin or the CTA1 fragment. The intracel-
lular trafficking of CT thus makes it difficult to correlate in
vitro assays of CTA1 activity with in vivo toxicity studies.
In this work, we assessed the toxicities of wild-type and
mutant forms of CTA1 by using a plasmid-based system to
directly express various CTA1 constructs in either the ER or
the cytosol of transfected cells. This system bypasses the ret-
rograde trafficking itinerary of CT and the need for intact
holotoxin. CTA1 activity (monitored by cAMP accumulation in
transfected cells) and CTA1 processing can therefore be ex-
amined without the confounding problems related to CT traf-
ficking. This in vivo expression system was combined with two-
hybrid studies and in vitro enzyme assays to assess the role(s)
of the CTA13 subdomain in ARF-stimulated toxin activity and
toxin entry into the cytosol. An intact CTA13 subdomain was
shown to be required for efficient interaction with ARF6 and
for full enzyme activity, but toxin entry into the cytosol was not
inhibited in an ER-localized CTA1 construct lacking the A13
subdomain. Toxin entry into the cytosol may instead depend
upon an inherent physical property of the CTA1 polypeptide.
MATERIALS AND METHODS
Materials. Lipofectamine and the pcDNA3.1 expression plasmid were pur-
chased from Invitrogen (Carlsbad, CA), the purified CTA1/CTA2 heterodimer
was from Calbiochem (La Jolla, CA), cell culture reagents were purchased from
Gibco BRL (Grand Island, NY), bacterial-culture reagents were from Fisher
Scientific (Pittsburg, PA), chemicals were from Sigma-Aldrich (St. Louis, MO),
[35S]methionine was from NEN Life Sciences (Boston, MA), and the [125I]cAMP
Biotrak kit was from Amersham-Pharmacia (Arlington Heights, IL). Immobi-
lized anti-CTA antibodies (5) were generated by a 4°C overnight incubation with
50 mg protein G-agarose (Sigma-Aldrich) in 1 ml of phosphate-buffered saline
(PBS) supplemented with 0.1% bovine serum albumin. Talon metal affinity resin
was from BD Biosciences (Palo Alto, CA).
Generation of CTA1 constructs. A T7-based clone expressing mature CTA1
with a C-terminal His6 tag was made in multiple steps by first replacing the
mature CTB gene from a derivative of pT7CTBR with XbaI deleted (16) with the
mature CTA1 gene from pNPCT (47) to make pT7CTA1. Then, the carboxyl end
of a CTA1 derivative encoded by pMGJ6701 (6) and a His6 tag derived from
pT7SH6 (43) were cloned together into pT7CTA1 in several steps to create
pT7CTA1h6, encoding a mature CTA1 polypeptide ending in CGNSHHHH
HHXX (single-amino-acid notation, where N is Asn-189 of mature CTA1 and
XX denotes two termination codons). A deletion of the A13 domain was first
made in a holotoxin backbone by cloning an XbaI-SmaI fragment of a PCR
product, made by using a vector primer and CTA13SmaR (CTCCCCGGGAA
ACCTGCCAATCC), into a derivative of a holotoxin-encoding clone, pMGJ142
(8), which has a silent mutation introducing an SmaI site encoding Pro-185/
Gly-186 of CTA1 to create pMGJ197. The XbaI-SmaI fragment was then
subcloned into an XbaI-EcoRI (filled-in) digest of pT7CTA1h6, creating
pT7CTA1d3h6, encoding CTA1 ending in GFPSHHHHHH (where P is Pro-
168 of mature CTA1).
For eukaryotic cytoplasmic expression of CTA1 derivatives, the wild-type CTA1h6
and CTA1d3h6 were moved into the backbone of pcDNA3.1/mCTA1 (42) to create
pcDNAmatCTA1h6 (encoding mCTA1·His6) and pcDNAmatCTA1d3h6 (encod-
ing mCTA11-168·His6), respectively. A native, non-His-tagged variant of the A13
deletion clone was made by replacing a HindIII-EcoRI fragment of pcDNA3.1/
mCTA1 with a similarly digested PCR fragment made using a T7 universal
primer and CTA1d3ER (GGGAATTCATTACGGAGGGAAACCTGCC),
which represents a mature CTA1 gene terminating at Pro-169. Inactivating
Glu-to-Asp mutations at residues 110 and 112 of mature CTA1 were moved into
pcDNA3.1/mCTA1 to create pcDNAmatCTA1dd (encoding mCTA1dd). Con-
struction of the pcDNA3.1 clones producing ssCTA1 and ssCTA1dd has been
described previously (42). The pcDNA3.1 clone encoding an ER-localized form
of the CTA13 deletion derivative was made by replacing a BglII-PflMI fragment
of pcDNAmatCTA1d3h6 with the same-cut fragment from pcDNA3.1/ssCTA1,
encoding the signal peptide of CTA1.
mCTA1·His6 and mCTA11-168·His6 protein purification. Escherichia coli strain
BL21(pLysS) was transformed with an inducible mCTA1·His6 or mCTA11-
168·His6 expression plasmid and grown at 37°C in 500 ml Luria-Bertani broth
(LB) (21) to an A600 of 0.6. CTA1 expression was then induced by addition of 1
mM IPTG (isopropyl--D-thiogalactopyranoside) to the growth medium. At 4 h
postinduction, the cells were pelleted, resuspended in Tris-buffered saline (TBS)
(20 mM Tris-HCl, pH 7.6, 137 mM NaCl) containing 8 M urea, and lysed with
three freeze-thaw cycles. The insoluble lysate fraction was removed after a
45-min spin at 10,000  g. The soluble fraction was then incubated with Talon
resin at room temperature for 30 min. The resin was subsequently poured into a
plastic column and washed with 10 column volumes of TBS containing 8 M urea.
The CTA1 construct was then eluted from the column with 8 to 10 column
volumes of elution buffer (TBS, 8 M urea, and 100 mM imidazole). One-milliliter
fractions were collected and analyzed by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) for the presence of CTA1. Before use in the
ADP-ribosylation assay, the fractions containing CTA1 were dialyzed against
three changes of 4 liters of TBS containing 2 M urea. With the use of a buffer
exchange column (Pierce, Rockford, IL), the dialyzed protein was transferred to
buffer containing 20 mM dithiothreitol (DTT), 0.1 mg bovine serum albumin/ml,
and 0.2 M potassium phosphate, pH 7.5.
ARF6 protein purification. E. coli strain BL21(pLysS) was transformed with an
inducible ARF6 expression plasmid (pT7Arf6; kindly provided by Joel Moss,
National Heart, Lung, and Blood Institute, Bethesda, MD) and grown at 37°C in
500 ml LB to an A600 of 0.6. ARF6 production was then induced by the addition
of 1 mM IPTG to the growth medium. At 4 h postinduction, the cells were
pelleted, resuspended in TBS, and lysed with three freeze-thaw cycles. The
insoluble lysate fraction was removed after a 45-min spin at 10,000  g. The
remaining soluble lysate was dialyzed against two changes of 4 liters low-salt
buffer (20 mM Tris, pH 7.6, 50 mM NaCl, and 1 mM EDTA). The sample was
then put over a DEAE column, and the flowthrough was collected. As assessed
by SDS-PAGE, the flowthrough contained ARF6 and very few other proteins.
The ARF6-enriched flowthrough was dialyzed against three changes of 4 liters
no-salt buffer (200 mM Tris, pH 7.6, 1 mM MgCl, and 1 mM DTT) and placed
over a Q-Sepharose column. The fraction containing ARF6 was eluted with
buffer containing 15 mM NaCl, 200 mM Tris, pH 7.6, 1 mM MgCl, and 1 mM
DTT. The purity of the eluted ARF6 was confirmed by SDS-PAGE and Coo-
massie staining.
Nondenaturing polyacrylamide gel electrophoresis. All samples, gels, and
electrophoresis buffers were prepared without SDS or DTT. The samples were
then run on a nondenaturing 12% polyacrylamide minigel in a Tris-glycine
buffer. The gels were run at 25 milliamps until the dye front reached the bottom
of the gel. The samples were then visualized with Coomassie stain.
Two-hybrid assay. Interactions between CTA1 derivatives and ARF6 were
determined using modifications of a bacterial two-hybrid assay (7). The A13
domain deletion from pMGJ197 was subcloned as an XbaI-ClaI fragment in
place of the native CTA1 domain of the pCTA1R7KT18 plasmid to create
pCTA1d3T18. Wild-type and deletion derivatives were coexpressed with
pCT25ARF6 in a new lac mal reporter strain, DC8, a cyaA1403::Km mutant
of E. coli MM294 (CGSC 6315 from New England Biolabs, Beverly, MA).
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Interaction was assessed by assaying the cAMP-induced production of -galac-
tosidase activity in log-phase cultures as described by Miller (21). The back-
ground signal (32 Miller units) from cells harboring pCT25arf6 and pAT18-9
vectors was subtracted from the presented experimental data.
ADP-ribosylation assay. Diethylamino(benzylidine-amino)guanidine (DEA-
BAG), an artificial substrate for ADP ribosylation that absorbs light at 355-nm
wavelength and loses its ability to bind to Bio-Rad AG (Hercules, CA). Ion-
exchange resin after ADP ribosylation, was synthesized as described previously
(34). Dilutions of the His6-tagged CTA1 protein were mixed with 2 mM DEA-
BAG in 0.2 ml of assay buffer (20 mM DTT, 0.1 mg bovine serum albumin/ml,
10 mM NAD, and 0.2 M potassium phosphate, pH 7.5). Where indicated, 10 g
ARF6 was also added to the assay buffer. After 2 h at 30°C, the reaction was
stopped by binding unreacted DEA-BAG with 1 ml of a 40% slurry of Bio-Rad
AG-50W-X4 resin. The DEA-BAG–Bio-Rad AG-50W-X4 suspension was vor-
texed for 30 s and spun for 10 min at full speed in a microcentrifuge; 0.4 ml of
the resulting supernatant was removed and analyzed for fluorescence (excitation
wavelength, 361 nm; emission wavelength, 440 nm) with a VersaFluor fluorom-
eter (Bio-Rad, Hercules, CA). Three reactions were performed for each data
point.
Cell culture and transfection. The Chinese hamster ovary (CHO) fibroblasts
used in this study are auxotrophic for proline and were provided by the late
Henry Wu (Uniformed Services University of the Health Sciences, Bethesda,
MD). The cells were maintained in Ham’s F-12 medium supplemented with 10%
fetal bovine serum. Growth conditions were set at 37°C and 5% CO2 in a
humidified incubator. For transient transfections, 1 g of plasmid DNA was
mixed with 5 l Lipofectamine for 20 min at room temperature. The mixture was
then added for 3 h to cells that had been seeded at 75% confluence in six-well
plates. The transfected cells were analyzed at either 4 or 16 h posttransfection
(cAMP assay) or at 16 to 24 h posttransfection (metabolic labeling).
Transfection-cAMP assay. Transfected cells were solubilized in 0.75 ml acidic
ethanol (1 N HCl-ethanol at a 1:100 ratio) for 15 min at 4°C. The cell extracts
were transferred to microcentrifuge tubes for a 10-min 4°C spin. The supernatant
was collected, and the pellet was reextracted with 0.75 ml of an ice-cold ethanol-
H2O solution at a 2:11 ratio. Supernatants from both extractions were combined
and lyophilized overnight. The lyophilized cell extracts were reconstituted in 1.5
ml of buffer, and cAMP levels in the reconstituted extracts were quantitated with
the use of a 125I-labeled cAMP Biotrak competition assay. Background cAMP
levels from cells transfected with the empty pcDNA3.1 vector (typically 1,000
fmol cAMP/well) were subtracted from the values obtained for our experimental
conditions.
Metabolic labeling and immunoprecipitation of native and truncated CTA1.
Transfected cells were washed twice with PBS, incubated in 0.5 ml methionine-
free medium for 1 h, and exposed to 0.5 ml of 150 Ci [35S]methionine/ml for
1 h. After two additional PBS washes, the cells were either solubilized in 1 ml
lysis buffer (25 mM Tris, pH 7.4, 20 mM NaCl, 1% deoxycholic acid, 1% Triton
X-100, 1 mM phenylmethylsulfonyl fluoride, 1 g pepstatin/ml, and 1 g leu-
peptin/ml) for 20 min at 4°C or returned to serum-free medium containing 0.5
mg methionine/ml. Additional cell extracts were generated immediately after the
specified chase intervals. Triton-insoluble material was removed from the cell
extracts by centrifugation, and immobilized anti-CTA antibodies were added to
the cleared supernatants for overnight incubation at 4°C. The immunoprecipi-
tated material was washed twice with NDET (1% Nonidet P-40, 0.4% deoxy-
cholic acid, 5 mM EDTA, 10 mM Tris, pH 7.4, 150 mM NaCl) and once with
water before resuspension in sample buffer. SDS-PAGE (15% polyacrylamide
gels) with phosphorimager analysis (Bio-Rad) was used to visualize and quanti-
tate the immunoisolated samples. Results for the chase intervals were expressed
as percentages of the values obtained from the pulse-labeled cells.
RESULTS
ARF interaction with CTA1 and CTA11-168. An established
bacterial two-hybrid assay (7) was used to confirm that an
intact A13 subdomain was required for CTA1 to interact with
ARF. With this assay, the catalytic domain of Bordetella per-
tussis adenylate cyclase was separated into two complementary
fragments (T25 and T18) that lacked adenylate cyclase activity.
The T25 fragment was fused to ARF6, and the T18 fragment
was fused to CTA1 or to a truncated CTA1 variant lacking the
A13 subdomain (CTA11-168). Both CTA1 constructs were de-
toxified with arginine 7-to-lysine substitutions in order to fa-
cilitate their expression in the cytoplasm of E. coli DC8 (7).
The T25-ARF6 and CTA1-T18 fusion proteins interacted to
produce functional adenylate cyclase, resulting in production
of intracellular cAMP and expression of the -galactosidase
reporter gene. In contrast, coexpression of T25-ARF6 and
CTA11-168-T18 produced only a minimal increase in the level
of genes encoding -galactosidase (Fig. 1), corresponding to
about 15% of the level observed with ARF6 and the full-length
CTA1 construct. Thus, the presence of the CTA13 subdomain
appeared to be important for the interaction of ARF6 with
CTA1.
In vitro activity of CTA1·His6 and CTA11-168·His6. To cor-
roborate the lack of interaction of CTA11-168 with ARF6, we
purified ARF6, CTA1, and CTA11-168 for use in an in vitro
ADP-ribosylation assay. Members of the ARF family of pro-
teins serve as allosteric activators of CTA1 (48), so the inability
of CTA11-168 to interact with ARF6 would be expected to
prevent any stimulatory effect of ARF6 on the enzymatic ac-
tivity of CTA11-168. Recombinant ARF6 was purified from
lysates of E. coli transformed with an inducible ARF6 expres-
sion plasmid. CTA1 and CTA11-168 were modified with a C-
terminal His6 tag for Talon column purification from lysates of
E. coli transformed with inducible CTA1 expression plasmids.
The recombinant CTA1 proteins were called mCTA1·His6 and
mCTA11-168·His6 to denote the mature CTA1 polypeptide (m)
and the His6 tag.
Two control experiments were performed to verify the in
vitro stabilities of mCTA1·His6 and mCTA11-168·His6 (Fig. 2).
First, nondenaturing PAGE resolved both mCTA1·His6 and
mCTA11-168·His6 as monomeric species with the expected mo-
bilities (Fig. 2A). Identical mobilities were observed for
mCTA1·His6 and the CTA1 polypeptide from a reduced
CTA1-CTA2 heterodimer. Next, an established protocol for
CTA unfolding and aggregation (50) failed to detect aggre-
gated (i.e., pelleted) forms of our His6-tagged constructs (Fig.
2B). These experiments demonstrated that mCTA1·His6 and
mCTA11-168·His6 were purified as soluble, monomeric pro-
teins.
FIG. 1. ARF6 interaction with CTA1 and CTA11-168 in a bacterial
two-hybrid system. The cAMP-dependent expression of -galactosi-
dase activity was measured from triplicate cultures of E. coli coexpress-
ing T25/ARF6 and CTA1/T18 or CTA11-168/T18. -Galactosidase ac-
tivity is expressed in Miller units and reflects the amount of cAMP
produced as a consequence of the interaction between ARF6 and
CTA1 or CTA11-168. The error bars represent standard deviations of
the mean.
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The enzymatic activities of mCTA1·His6 and mCTA11-168·
His6 were assessed by ADP ribosylation of the substrate DEA-
BAG (Fig. 3). The activity of mCTA1·His6 was stimulated
7-fold by the addition of ARF6 (Fig. 3A). In contrast, no
stimulation of mCTA11-168·His6 activity was observed in the
presence of ARF6 (Fig. 3B). mCTA11-168·His6 was also less
active than mCTA1·His6, exhibiting only 14% of the basal
catalytic activity of an equimolar amount of full-length CTA1.
Removal of the CTA13 subdomain thus decreased the catalytic
activity of mCTA11-168·His6 and abolished the stimulation of
its catalytic activity by ARF6.
In vivo activities of CTA1 and CTA11-168/9. To examine the
in vivo activities of our CTA1 constructs, the coding sequences
of mCTA1·His6 and mCTA11-168·His6 were introduced into
the pcDNA3.1 eukaryotic expression vector for use in a trans-
fection-cAMP assay. With this assay, a plasmid-based system
was used to produce mature CTA1 constructs directly in the
cytosol of transfected CHO cells. cAMP levels in transfected
cells were then used as a measure of CTA1 activity against
Gs. Previous work showed that transfected, CTA1-produc-
ing CHO cells produce a cAMP response within 4 hours of
posttransfection chase (42). If the in vivo activity of CTA1
required ARF interaction, this cAMP response would be
expected to be markedly decreased or absent from cells
producing CTA11-168·His6.
Transfected cells producing either mCTA1·His6 or mCTA11-168·
His6 generated detectable cAMP responses at both 4 and 16 h
of posttransfection chase (Fig. 4). Cells producing mCTA11-168·
His6 produced a cAMP signal that was 1.4 times above back-
ground at 4 h of chase. This signal rose to 7.3 times above
background by 16 h of chase. However, cells producing the
full-length mCTA1·His6 construct produced substantially more
cAMP than cells expressing mCTA11-168·His6 at both 4 and
16 h of chase. mCTA11-168·His6 thus exhibited a basal level of
ADP-ribosyltransferase activity that was sufficient to cause an
easily detectable increase in production of cAMP in vivo, but it
was significantly less active than the full-length mCTA1·His6
construct.
Transfected cells synthesized 2.3-fold more mCTA11-168·His6
than mCTA1·His6 (data not shown; n  4). When the raw
cAMP responses presented in Fig. 4 were corrected for this
difference in the CTA1 production level, we found that
mCTA11-168·His6 produced 15% (4-h chase) or 29% (16-h
chase) of the cAMP signal obtained with mCTA1·His6.
The C-terminal His6 tag could potentially alter the catalytic
activities of mCTA1·His6 and mCTA11-168·His6. To control for
this possibility, we repeated the transfection-cAMP assay with
untagged variants of mCTA1 and mCTA11-168 (Fig. 5). An
untagged mCTA1 variant with glutamate-to-aspartate substi-
tutions at residues 110 and 112 in the CTA1 active site was also
examined in these studies. This construct is called mCTA1dd
to denote the mature CTA1 polypeptide (m) and the two
active-site mutations (dd). CT holotoxin variants containing
glutamate-to-aspartate substitutions at either residue 110 or
112 in CTA1 exhibited less than 1% of wild-type holotoxin
enzyme activity in vitro (5).
CHO cells expressing the genes for mCTA1dd, mCTA11-168,
or mCTA1 were assayed for cAMP content at 4 and 16 h of
FIG. 2. In vitro stabilities of mCTA1·His6 and mCTA11-168·His6.
(A) One-microgram samples of the reduced CTA1/CTA2 heterodimer
(lane 1), mCTA11-168·His6 (lane 2), and mCTA1·His6 (lane 3) were re-
solved by nondenaturing PAGE and visualized by Coomassie staining.
(B) Three hundred nanograms of mCTA1·His6 and mCTA11-168·His6
were incubated at 4°C or 30°C for 20 min before a 15-min, 4°C spin at
16,000  g. The input (i) starting material, as well as the resulting super-
natants (s, reflecting soluble protein) and pellets (p, reflecting aggregated
protein) were visualized by SDS-PAGE with Coomassie staining.
FIG. 3. ARF6 stimulation of mCTA1·His6 and mCTA11-168·His6 en-
zyme activity. Twofold dilutions of mCTA1·His6 (A) or mCTA11-168·His6
(B) were mixed with 2 mM DEA-BAG in 0.2 ml of ADP-ribosylation
assay buffer. Toxins were incubated in the absence (circles) or presence
(squares) of ARF6. After 2 h at 30°C, the reaction was stopped. The
ADP-ribosylation of DEA-BAG was then assessed by fluorometry; in-
creasing fluorescent units correspond to increasing levels of ADP ribosy-
lation. Assays with mCTA1·His6 and mCTA11-168·His6 were performed in
parallel but are shown on separate graphs because of the difference in
scale. In the absence of ARF, mCTA11-168·His6 exhibited only 14% of the
activity recorded for an equimolar amount of mCTA1·His6 (n  2), and
ARF6 failed to stimulate the catalytic activity of mCTA11-168·His6. Three
reactions were performed for each data point; the error bars represent the
standard deviations.
FIG. 4. In vivo activity of mCTA1·His6 and mCTA11-168·His6.
cAMP levels in transfected CHO cells expressing mCTA1·His6 or
mCTA11-168·His6 were determined at 4 and 16 h of posttransfection
chase. Background levels of cAMP (typically 1,000 fmol cAMP/well)
from cells transfected with an empty vector were subtracted from the
experimental results. Duplicate samples were used for each experi-
ment; the graph presents the means 	 standard deviations of the
means of four independent experiments.
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posttransfection chase (Fig. 5A). mCTA1-producing cells gen-
erated a robust cAMP response at 4 h of chase, but only a
minimal cAMP response was recorded at 4 h of chase for cells
expressing mCTA1dd or mCTA11-168. However, by 16 h of
chase, all three mCTA1 constructs elicited easily detectable
increases in the cAMP responses from transfected cells. These
results were consistent with the data obtained for the His6-
tagged constructs and demonstrated that mCTA11-168 was a
weak but functional toxin that exhibited significantly more
activity than mCTA1dd. The data also demonstrated the high
sensitivity of this system for detecting low residual levels of
catalytic activity in the mutant forms of CTA1.
Transfected cells synthesized 1.8-fold more mCTA1 than
mCTA1dd and 2.4-fold more mCTA1 than mCTA11-168. After
standardizing the data in Fig. 4A to these differences in ex-
pression levels, the activities of mCTA1dd and mCTA11-168
were expressed as percentages of mCTA1 activity (Fig. 5B).
mCTA1dd exhibited only 12 to 19% of the activity recorded for
mCTA1 over the course of the experiment. In contrast, the
relative activity of mCTA11-168 increased dramatically over the
course of the experiment: mCTA11-168 exhibited only 9% of
the activity recorded for mCTA1 at 4 h of chase, but at 16 h of
chase, mCTA11-168 exhibited 54% of mCTA1 activity.
CTA1 constructs that were expressed directly in the eukary-
otic cytosol were used to generate the data presented in Fig. 5.
Essentially identical results were obtained when CTA1dd,
CTA11-169, and CTA1 were initially directed into the ER lu-
men (Fig. 6). Cotranslational insertion of CTA1 variants into
the ER was accomplished by placing the coding region for the
CTA signal sequence directly upstream of the mCTA1dd,
mCTA11-169, or mCTA1 coding sequence. The resulting vari-
ants are referred to as ssCTA1dd, ssCTA11-169, and ssCTA1 to
FIG. 5. In vivo activity of mCTA1dd, mCTA11-168, and mCTA1. (A) cAMP levels in transfected CHO cells expressing mCTA1dd, mCTA11-168,
or mCTA1 were determined at 4 and 16 h of posttransfection chase. Background levels of cAMP (typically 1,000 fmol cAMP/well) from cells
transfected with an empty vector were subtracted from the experimental results. Duplicate samples were used for each experiment; the graph
presents the means 	 standard errors of the means of four independent experiments. (B) The cAMP responses of cells expressing mCTA1dd or
mCTA11-168 were calculated as percentages of the cAMP response from cells expressing mCTA1. SDS-PAGE and phosphorimager analysis were
used to quantitate the pools of mCTA1dd, mCTA11-168, and mCTA1 immunoprecipitated from metabolically labeled cells at 16 h posttransfection
chase. Transfected cells synthesized 1.8-fold more mCTA1 than mCTA1dd and 2.4-fold more mCTA1 than mCTA11-168. The data presented in
panel A were standardized to these differences in CTA1 expression levels before the relative activities of mCTA1dd and mCTA11-168 were
determined. The means plus standard deviations of the means of four independent experiments are presented in the graph.
FIG. 6. In vivo activity of ssCTA1dd, ssCTA11-169, and ssCTA1. (A) cAMP levels in transfected CHO cells expressing ssCTA1dd, ssCTA11-169,
or ssCTA1 were determined at 4 and 16 h of posttransfection chase. Background levels of cAMP (typically 1,000 fmol cAMP/well) from cells
transfected with an empty vector were subtracted from the experimental results. Duplicate samples were used for each experiment; the graph
presents the means plus standard errors of the means of four independent experiments. (B) The cAMP responses of cells expressing ssCTA1dd
or ssCTA11-169 were calculated as percentages of the cAMP response from cells expressing ssCTA1. The data presented in panel A were
standardized to differences in CTA1 expression levels before the relative activities of ssCTA1dd and ssCTA11-169 were determined. The means plus
standard deviations of the means of four independent experiments are presented in the graph.
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denote the presence of the CTA signal sequence (ss). In eu-
karyotes, the CTA signal sequence acts as a targeting deter-
minant for cotranslational delivery of CTA1 into the ER lumen
and is proteolytically removed from CTA1 in the ER. Protease
protection assays, complete cleavage of the CTA signal se-
quence, and the addition of oligosaccharides to recombinant
CTA1 constructs with N-linked glycosylation sites have dem-
onstrated that the entire pool of newly synthesized CTA1 is
inserted into the ER lumen when the CTA signal sequence is
present (30, 39). The ER-localized pool of CTA1 is then trans-
ferred to the cytosol and degraded by the proteasome in a
process involving the ERAD mechanism (39).
The transfection-cAMP assay was performed with constructs
producing ssCTA1dd, ssCTA11-169, and ssCTA1 in order to
examine the role of the A13 subdomain in CTA1 export from
the ER to the cytosol. If a hydrophobic region in the A13
subdomain served as a trigger to promote ERAD-mediated
passage of CTA1 into the cytosol, then truncation of the A13
subdomain would be expected to eliminate the signal for ex-
port and prevent CTA1 from entering the cytosol. As such,
ssCTA11-169 would fail to elicit a cAMP response from trans-
fected cells because it would not exit the endomembrane sys-
tem to reach its Gs target in the cytosol. However, in contrast
to this model, we found that ssCTA11-169 was as toxic as
mCTA11-168: the ER-localized and cytosolic variants of
CTA11-168/9 both generated 80 fmol cAMP/well at 4 h of
chase and 4,000 to 7,000 fmol cAMP/well at 16 h of chase (Fig.
5A and 6A). Thus, it appeared that the A13 subdomain was not
required for CTA1 passage into the cytosol.
As with the mCTA1 variants, the raw data presented for the
ssCTA1 constructs in Fig. 6A were corrected for differences in
CTA1 expression levels and expressed as percentages of wild-
type ssCTA1 activity (Fig. 6B). ssCTA1dd exhibited only 13 to
22% of the activity recorded for ssCTA1 over the course of the
experiment. In contrast, the relative activity for ssCTA11-169
increased substantially from 4 h to 16 h of posttransfection
chase, from 8% of the activity recorded for ssCTA1 at 4 h of
chase to 44% of the activity recorded for ssCTA1 at 16 h of
chase. The nearly equivalent relative activities of mCTA11-168
and ssCTA11-169 at both 4 h (10% of wild-type activity) and
16 h (50% of wild-type activity) of posttransfection chase
again demonstrated that the removal of the A13 subdomain
did not prevent ER-localized CTA1 from reaching its cytosolic
target. The similar results obtained with mCTA11-168 and ss-
CTA11-169 also indicated that, over the course of a 4- or 16-h
experiment, the ER-to-cytosol export of ssCTA1 was not a
rate-limiting event for CTA1 interaction with Gs. This inter-
pretation is supported by our previous work, which demon-
strated a relatively rapid rate of CTA1 export from the ER to
the cytosol (39). Collectively, our data suggest that the CTA13
subdomain is required for efficient expression of enzyme ac-
tivity but not for toxin entry into the cytosol.
Intracellular degradation of CTA1 and CTA11-168/9. To fur-
ther examine the role of the A13 subdomain in CTA1 export
from the ER to the cytosol, we monitored the intracellular
processing of ssCTA1 and ssCTA11-169 (Fig. 7A). The ER-
localized pool of CTA1 is transferred to the cytosol and de-
graded in a proteasome-dependent manner (36, 37). If the A13
subdomain contains the trigger for export from the ER, then
export of ssCTA11-169 to the cytosol would be expected to be
slower than that of ssCTA1, resulting in decreased proteolysis
and an increase in the half-life for ssCTA11-169 relative to
ssCTA1.
To test this hypothesis, CHO cells producing ssCTA1 or
ssCTA11-169 were preincubated in methionine-free medium
for 1 h, labeled with 150 Ci [35S]methionine/ml for 1 h, and
chased for various intervals in serum-free medium containing
an excess of unlabeled methionine. Cell extracts generated
after the stated intervals were subjected to immunoprecipita-
tion with immobilized anti-CTA antibodies. The immunoiso-
lated samples were then resolved by SDS-PAGE. Phosphor-
imager quantitation of the immunoisolated samples demonstrated
that ssCTA1 and ssCTA11-169 were degraded at identical rates,
with 2-h half-lives (Fig. 7A). We found that mCTA1 and
mCTA11-168, produced as cytoplasmic proteins, also exhibited
2-h half-lives (Fig. 7B). These results were consistent with
the data obtained from our transfection-cAMP assays and
demonstrated that the A13 subdomain does not play an essen-
tial role in CTA1 export from the ER to the cytosol.
ERAD substrates are efficiently retained in the proximal
compartments of the secretory pathway before passage into the
cytosol for proteasome-mediated degradation (11, 20, 46). The
processing of ER-localized CTA1 occurs in a similar manner
(39). To ensure that ssCTA11-169 was also processed as an
ERAD substrate, we monitored the turnover of ssCTA11-169
in cells exposed to N-acetyl-Leu-Leu-Norleu-Al (ALLN),
brefeldin A (BfA), or NH4Cl (Fig. 8). ALLN inhibits the pro-
teasome (12), BfA inhibits trafficking through the secretory
pathway (10), and NH4Cl inhibits the activity of acid-depen-
FIG. 7. Degradation of CTA1 and CTA11-168/9. (A) Transfected
CHO cells expressing ssCTA1 (circles) or ssCTA11-169 (squares) were
incubated for 1 h with 150 Ci [35S]methionine/ml and chased in
serum-free medium containing an excess of cold methionine. Anti-
CTA immunoprecipitates from cell extracts generated at the stated
intervals were visualized and quantitated by SDS-PAGE with phosphor-
imager analysis. Results for the chase intervals were expressed as per-
centages of the values obtained from the pulse-labeled cells. One of
four independent experiments is presented in the gel. The graph pre-
sents the means 	 standard errors of the means of all four experi-
ments. (B) Experiments identical to the ones described above were
performed with transfected CHO cells expressing mCTA1 (circles) or
mCTA11-168 (squares). One of four independent experiments is pre-
sented in the gel. The graph presents the means 	 standard deviations
of the means of all four experiments.
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dent lysosomal proteases (31). The 2-h half-life of ssCTA11-169
was extended to just over 3 h in ALLN-treated cells, thus
demonstrating a role for the proteasome in ssCTA11-169 deg-
radation. However, neither BfA nor NH4Cl had a significant
impact on the turnover of ssCTA11-169. Furthermore, no se-
creted pools of ssCTA11-169 were detected in the extracellular
medium of our transfected cells (data not shown). These re-
sults collectively demonstrated that ssCTA11-169 was processed
as an ERAD substrate despite the absence of the A13 subdo-
main and its putative hydrophobic trigger for ERAD recog-
nition.
DISCUSSION
Previous work has shown that certain hydrophobic residues
in the CTA13 subdomain are important for ARF association
with CTA1 (7). A C-terminal hydrophobic region in the A1
polypeptide of E. coli heat-labile toxin, which is 80% homolo-
gous to CTA1, is also required for interaction with the ARF
proteins (53). In this work, we found that an intact CTA13
subdomain was essential for a functional interaction between
ARF6 and CTA1. Our two-hybrid assay demonstrated that the
level of interaction between ARF6 and CTA11-168 was only
15% of that observed for ARF6 and full-length CTA1. Addi-
tional experiments with purified proteins showed that ARF6
failed to stimulate the catalytic activity of mCTA11-168 · His6.
Our data thus provide physical and functional evidence for the
role of the CTA13 subdomain in ARF stimulation of CTA1
activity.
The recently published CT/ARF6 cocrystal suggests that
ARF6 binding to CTA1 does not require amino acids 168 to
192 of CTA1 (24). However, our results here show that ARF6
does not physically or functionally interact with CTA11-168.
This simply indicates that the inhibition of ARF6 binding to
CTA1 can result from structural effects other than loss of the
specific ARF6 binding site. For example, we have previously
suggested that the surface exposure of certain aromatic amino
acids in the A13 subdomain may create an initial ARF inter-
action motif (7). Alternatively, deletion of the A13 subdomain
may induce a conformational change in CTA11-168 that inhibits
ARF6 binding. Either possibility is consistent with the collec-
tive results of the current study and the CT/ARF6 cocrystal
study.
CTA11-168/9 variants were able to produce attenuated and
time-dependent cAMP responses in transfected CHO cells,
despite their inability to interact with ARF: mCTA11-168 and
ssCTA11-169 elicited 8 to 9% of the cAMP responses obtained
from cells producing the corresponding full-length CTA1 con-
structs at 4 h of chase, but by 16 h of chase the CTA11-168/9
variants generated 44 to 54% of the cAMP responses from
full-length CTA1-producing cells. The time required for sub-
stantial cAMP accumulation in cells producing mCTA11-168 or
ssCTA11-169 was a consequence of the low basal activity of
CTA11-168/9 and is consistent with a time-dependent increase
in the cellular levels of ADP-ribosylated Gs and activated
adenylate cyclase. These findings indicate that ARF stimula-
tion of CTA1 activity may facilitate, but is not required for,
activation of adenylate cyclase in target cells.
The cAMP responses of CTA1dd-producing cells were much
less dramatic than the responses from CTA11-168/9-producing
cells. For cells expressing mCTA1dd or ssCTA1dd, cAMP levels
rose by a factor of only 1.7 from 4 h to 16 h of posttransfection
chase. In contrast, for cells expressing mCTA11-168 or ssCTA11-169
there was a sixfold increase in cAMP levels from 4 to 16 h of
chase. The differential cAMP responses of CTA1dd-producing
cells versus CTA11-168/9-producing cells could not be attributed to
differences in protein turnover, as ssCTA1dd had the same 2-h
half-life as ssCTA11-169 (data not shown). These findings suggest
that the balance between toxin activity and toxin degradation is
less favorable for CTA1dd than for CTA11-168/9 and that the basal
enzymatic activity of CTA1dd was not sufficient to produce a
substantial increase in the pool of ADP-ribosylated Gs in vivo
during the interval from 5 to 16 h posttransfection. Previous
studies have also suggested that the intoxication of target cells
involves a balance between toxin activity and toxin degradation (1,
41, 49).
Both the CTA1dd and CTA11-168/9 variants exhibited sub-
stantially more activity in vivo than in vitro. Differences be-
tween in vivo and in vitro activities have also been reported for
FIG. 8. ERAD processing of ssCTA11-169. Transfected CHO cells
incubated with 150 Ci [35S]methionine/ml for 1 h were chased in
serum-free medium containing excess cold methionine for the indi-
cated times. Exposure to 100 M ALLN (squares), 1 g BfA/ml
(triangles), or 20 mM NH4Cl (diamonds) was begun 1 h prior to
labeling and was maintained throughout the experiment. Untreated
cells are represented by circles. Anti-CTA immunoprecipitates from
cell extracts generated at the stated intervals were visualized and quan-
titated by SDS-PAGE with phosphorimager analysis. Results for the
chase intervals were expressed as percentages of the values obtained
from the pulse-labeled cells. One of four independent experiments is
presented in the gel; the graph presents the means 	 standard devia-
tions of the means of all four experiments.
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the plasmid-encoded toxin of enteroaggregative E. coli: a vari-
ant of this toxin with no in vitro activity was found to have
substantial in vivo activity when synthesized directly in the
eukaryotic cytosol with a plasmid-based expression system
(37). Collectively, these results simply indicate that in vivo and
in vitro assay conditions are not always equivalent.
The hydrophobic CTA13 subdomain was necessary for a
functional interaction with ARF6 but was dispensable for toxin
entry into the cytosol. Results from the transfection-cAMP
assay established that the ER-localized ssCTA11-169 variant
was as toxic as the cytosolic mCTA11-168 construct. Since elim-
ination of the CTA1 export signal would be expected to pre-
vent ER-localized CTA1 from reaching its Gs target in the
cytosol, the similar in vivo activities of ssCTA11-169 and
mCTA11-168 demonstrated that residues in the A13 subdomain
were not required to trigger ERAD-mediated passage of
CTA1 into the cytosol.
Data from our transfection-cAMP assay could potentially be
affected by a small, undetectable pool of ssCTA11-169 that was
mistargeted and synthesized directly in the cytosol. However, the
processing of metabolically labeled ssCTA11-169 by transfected
CHO cells also indicated that the A13 subdomain was not re-
quired for toxin entry into the cytosol. An inhibition of export
from the ER to the cytosol prevents the proteasome-mediated
degradation of CTA1 (40), yet ssCTA11-169 was degraded at the
same rate as the full-length ssCTA1 construct. No secreted pools
of ssCTA11-169 were detected, and the proteasome-dependent
turnover of ssCTA11-169 was unaffected by treatments that inhibit
lysosomal proteolysis or trafficking in the secretory pathway.
Thus, although ssCTA11-169 lacked the A13 subdomain and the
putative trigger for entry into the cytosol, it was efficiently re-
tained in the ER and exported to the cytosol for proteasomal
degradation by the ERAD system. These experiments, which
directly monitored CTA1 protein levels and would not be affected
by a small pool of mistargeted ssCTA11-169 in the cytosol, pro-
vided independent support for our interpretation of Fig. 6—
namely, that the A13 subdomain does not contain the sole
signal for ERAD recognition and processing of CTA1.
It was possible that the normal signal for CTA1 entry into the
cytosol was located in the A13 subdomain, but removal of this
region generated a misfolded CTA1 variant that was still recog-
nized by the ERAD system. Export of ssCTA11-169 to the cytosol
might therefore result from a general defect in protein folding
rather than from a specific trigger residing in the ssCTA11-169
polypeptide. Based on the crystal structure of CTA1, truncation
of the A13 subdomain would not generate obvious difficulties for
protein folding. A flexible, 28-amino-acid molecular tether (the
A12 subdomain) links the A13 subdomain to the compact, cata-
lytic A11 subdomain (52). The structures of the globular A11
subdomain and the flexible A12 linker would thus likely remain
intact in CTA1 constructs lacking the A13 subdomain. Three
experimental findings also suggested that the CTA11-168/9 variants
were not dramatically misfolded: (i) all truncated CTA1 con-
structs retained some enzymatic and biological activity; (ii) the
CTA11-168/9 variants were degraded with the same kinetics, but
not faster than, the corresponding full-length CTA1 variants; and
(iii) all truncated CTA1 variants retained the capacity to bind
anti-CTA antibodies and to be recovered by immunoprecipita-
tion. A grossly misfolded protein would not be expected to retain
biological activity, yet all three CTA11-168/9 variants exhibited
readily detectable in vivo enzyme activity after 16 h of posttrans-
fection chase. Furthermore, a misfolded protein would likely be
degraded at a higher rate than a properly folded variant of the
same protein. The identical half-lives of ssCTA11-169 and ssCTA1
(as well as mCTA11-168 and mCTA1) thus indicated that the
structural organization of CTA1 was not dramatically altered by
deletion of the A13 subdomain. Finally, the ability to immuno-
precipitate CTA11-168/9 with anti-CTA antibodies indicated that
the CTA1 epitopes required for anti-CTA antibody interaction
were preserved in the truncated variants. As the CTA11-168/9
constructs appeared to fold properly, our findings do not support
the hypothesis that the A13 subdomain contains the sole signal for
ERAD recognition and translocation of CTA1 into the cytosol.
The signal for ERAD-mediated export to the cytosol may
reflect an inherent physical property of CTA1 rather than a
specific region or motif within the polypeptide. Fourier-trans-
form infrared spectroscopy has shown that the structural sta-
bility of CTA1 is temperature dependent, with a loss of CTA1
secondary structure in the disulfide-bridged CTA1/CTA2 het-
erodimer occurring between 40°C and 46°C (38). Furthermore,
circular dichroism and fluorescence techniques have recently
shown that the reduced CTA1/CTA2 heterodimer is in a fully
folded conformation at 25°C and a partially unfolded state at
37°C (K. Teter, D. Moe, A. H. Pande, M. G. Jobling, J. K.
Tinker, S. A. Tatulian, and R. K. Holmes, submitted for pub-
lication). It has also been reported that, in the absence of
ARFs or phospholipids, the reduced CTA1/CTA2 heterodimer
has greater enzymatic activity in vitro at 25°C than at 37°C (22).
Thermal instability in the reduced CTA1 polypeptide thus gen-
erates a partially unfolded conformation at 37°C, and this
unfolded state could act as the trigger for ERAD-mediated
export of CTA1 to the cytosol. In vivo, ARF and/or phospho-
lipid activation of CTA1 might stabilize the active conforma-
tion of CTA1 or compensate for a decreased basal level of
enzymatic activity resulting from a partially unfolded CTA1
conformation (22).
In conclusion, CTA1 utilizes the A13 subdomain for func-
tional interaction with ARF6 and for efficient expression of in
vivo enzyme activity. Surprisingly, however, the A13 subdo-
main is not required for ERAD-mediated toxin passage into
the cytosol. Thermal instability at 37°C may instead generate a
partially unfolded CTA1 polypeptide that is recognized by the
ERAD system as a signal for export to the cytosol. Work is
under way to examine this possibility.
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